Back to Search Start Over

2095 Survival benefit, safety, and prognostic factors for outcome with Regorafenib (RE) in patients (pts) with pretreated metastatic colorectal cancer (mCRC). Main analyses of the REBECCA study

Tools

Authors Abstract Subjects Details